Eberhard Standl

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Diabetes Management, Cardiovascular Disease, Health Policy +10

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong et al. · New England Journal of Medicine · 2015 · 2.5K citations · Full text

Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes

Bo Åhrén, Ramón Gomis, Eberhard Standl et al. · Diabetes Care · 2004 · 485 citations · Full text

Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply

Lars Rydén, Eberhard Standl · European Heart Journal · 2007 · 365 citations

Obesity, Metabolic Syndrome, Adjunct Therapy +8

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Rury R. Holman, Ruth L. Coleman, Juliana C.N. Chan et al. · The Lancet Diabetes & Endocrinology · 2017 · 316 citations

Metabolic Syndrome, Glucose Tolerance, Diabetes Management +10